Genetic Modulation of Working Memory in Attention Deficit Hyperactivity Disorder (ADHD)

PHASE3CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

December 31, 2012

Study Completion Date

March 31, 2013

Conditions
ADHD
Interventions
DRUG

Methylphenidate, non-retard

Medication (methylphenidate, non-retard) will be titrated to optimal response within 6 weeks, with a maximum of 10 mg/day in week 1, 20 mg/day in week 2, 30 mg/day in week 3, 40 mg/day in week 4, 50 mg/day in week 5, and 60 mg/day in week 6, unless adverse effects emerged. After successful adjustment, medication will be maintained until week 6. Dosing will be based on at least two-weekly evaluations by a psychiatrist, including an interview with a review of symptoms and side effects, completion of the Clinical Global Impression (CGI) scale and completion of a standardised Side Effects Rating Scale for psychostimulants (SERS). The maximal daily dosage of MPH is 60 mg. Within this double blind study the same procedure is applied for the placebo condition.

DRUG

Placebo

Trial Locations (1)

Unknown

Clinic for Psychiatrie, Psychosomatics and Psychotherapy, Würzburg

Sponsors
All Listed Sponsors
collaborator

German Research Foundation

OTHER

lead

Wuerzburg University Hospital

OTHER